BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCTX 0.81 -0.43(-34.68%)
Will BCTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCTX
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
BCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCTX
BriaCell dips despite promising mid-stage data for breast cancer therapy
BriaCell Achieves Breakthrough in Breast Cancer Treatment
BriaCell reports anti-tumor response in patient treated in Phase 2 study
BriaCell Therapeutics Launches $5 Million Offering
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients